PainchekASX:PCK +4.17% ROE % is -1,364.88% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 628 Healthcare Providers & Services companies, Painchek ranks worse than 98.89% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Painchek's annualized net income for the quarter that ended in Dec. 2025 was A$-9.40 Mil. Painchek's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was A$0.69 Mil. Therefore, Painchek's annualized ROE % for the quarter that ended in Dec. 2025 was -1,364.88%.
The historical rank and industry rank for Painchek's ROE % or its related term are showing as below:
ASX:PCK'
s ROE % Range Over the Past 10 Years
Min: -8668.93 Med: -288.19 Max: -87.56
Current: -747.85
During the past 13 years, Painchek's highest ROE % was -87.56%. The lowest was -8,668.93%. And the median was -288.19%.
ASX:PCK's ROE % is ranked worse than 98.89% of 628
companies
in the Healthcare Providers & Services industry
Industry Median: 5.72
vs ASX:PCK: -747.85
Painchek (ASX:PCK) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Painchek ROE % Related Terms
Painchek ROE % Historical Data
* Premium members only.
The historical data trend for Painchek's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Painchek's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Painchek ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Painchek's ROE % distribution charts can be found below:
* The bar in red indicates where Painchek's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Painchek (ASX:PCK) has a ROE % of -1,364.88% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Painchek and its competitors. According to the industry distribution chart, Painchek ranks #621 out of 628 companies in the Healthcare Providers & Services industry, placing it in the top 98.9%.
Is Painchek's ROE % too high?
Painchek's current ROE % is -1,364.88%. Based on the distribution chart, Painchek ranks #621 out of 628 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Painchek's ROE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Painchek ranks #621 out of 628 companies for ROE %. This places Painchek in the lower half of its industry. The industry median ROE % is 5.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.72, based on 628 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Painchek and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Painchek's current ROE % is -1,364.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Painchek stock overvalued right now?
Based on GuruFocus' analysis, Painchek (ASX:PCK) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.40, compared to a current price of A$0.10 — trading 75% below its estimated fair value. The current ROE % is -1,364.88%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Painchek (ASX:PCK), the current ROE % is -1,364.88% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Painchek Ltd is engaged in the development and commercialization of mobile medical device applications that provide pain assessment for individuals who are unable to communicate pain with carers. It operates in one segment, namely the sale of its pain assessment solutions. Its geographic segments include Australia, the United Kingdom, and Other countries, of which it generates the majority of its revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PCK has been successfully added to your 